Log in
Enquire now
Oisin Biotechnologies

Oisin Biotechnologies

Oisin develops anti-aging treatments that target and remove senescent cells, a type of damaged cell that is unable to divide, accumulates during aging and contribute to age-related diseases.

OverviewStructured DataIssuesContributors

Contents

oisinbio.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Therapy
Therapy
‌
Anti-Aging
Drug development
Drug development
Oncology
Oncology
Therapeutics
Therapeutics
‌
Ageing
...
Location
Seattle
Seattle
B2X
B2B
B2B
CEO
‌
Matthew Scholz
Founder
‌
Garry Hudson
‌
Matthew Scholz
AngelList URL
angel.co/company/oi...echnologies
Pitchbook URL
pitchbook.com/profiles...170081-92
Date Incorporated
2014
Spinout
OncoSenX
OncoSenX
Number of Employees (Ranges)
11 – 50
Email Address
info@oisinbio.com
Phone Number
+12068801166
Number of Employees
16
Full Address
701 Fifth Avenue Suite 4200 Seattle, WA 98104 United States
Investors
‌
Kizoo Technology Capital
Kingsley Advani
Kingsley Advani
Avant Global
Avant Global
Hedgewood
Hedgewood
KIZOO
KIZOO
Designer Fund
Designer Fund
Founded Date
2005
0
Total Funding Amount (USD)
7,100,000
Latest Funding Round Date
May 27, 2021
Latest Funding Type
‌
Venture round
Patents Assigned (Count)
1
Wellfound ID
oisin-biotechnologies
Country
United States
United States

Other attributes

Company Operating Status
Active

Osin Biotechnologies is a biotechnology company using DNA-targeting interventions to reduce pathologies associated with aging and to increase longevity that is headquartered in Seattle, Washington and was founded in 2014 by Garry Hudson and Matthew Scholz.

Oisin is targeting senescent cells due to their connections with age-related diseases. Senescent cells are cells that have been irreversibly damaged and cease dividing. The mechanism is thought to prevent damaged cells from turning cancerous. Senescent cells secrete molecules causing inflammation, which normally attracts immune cells for clearance of these cells but aging results in accumulation of these cells. Clearing of senescent cells has been shown to reduce negative effects of aging and to extend lifespan in mice.

SENSOlytics is the proprietary technology of Oisin. The system introduces an exogenous apoptotic gene transiently into cells that is expressed only in cells that have an active p16 gene. Expression of p16 is a characteristic of senescent cells. The senescent cells are induced to commit suicide and their system is reduces senescent cells by 80% in cell culture and significant reductions are reported in naturally aged mice.

Founding investors include the Methuselah Foundation and Sens Research Foundation and other investors include Kizoo Technology Ventures and the Methuselah Fund.

Spinout company OncoSenX is using similar technology to target and kill cancer cells.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

An Interview with Gary Hudson of Oisin Biotechnologies, Senescent Cell Clearance Startup

Reason

https://www.fightaging.org/archives/2016/02/an-interview-with-gary-hudson-of-oisin-biotechnologies-senescent-cell-clearance-startup/

Web

John Lewis at Undoing Aging 2018

https://www.youtube.com/watch?v=frWklN81hz4

May 30, 2018

Surviving the Zombie Cell Apocalypse with Stephen Hilbert from Oisin Biotechnologies

https://www.youtube.com/watch?v=zcDcSWq560s

September 7, 2018

The rise of Oisin Biotechnologies

Ariel VA Feinerman

https://medium.com/@arielf/the-rise-of-oisin-d4664ed7e9

Web

References

Find more companies like Oisin Biotechnologies

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.